Rocuronium pharmacodynamic models for published five pharmacokinetic models: age and sex are covariates in pharmacodynamic models

被引:5
|
作者
Masui, Kenichi [1 ,2 ]
Ishigaki, Sayaka [2 ,3 ]
Tomita, Atsuko [2 ]
Otake, Hiroshi [1 ]
机构
[1] Showa Univ, Sch Med, Dept Anesthesiol, Shinagawa Ku, Hatanodai 1-5-8, Tokyo 1428666, Japan
[2] Natl Def Med Coll, Dept Anesthesiol, Tokorozawa, Saitama 3598513, Japan
[3] Self Def Force Yokosuka Hosp, Dept Anesthesiol, Yokosuka, Kanagawa 2370071, Japan
关键词
Neuromuscular blockade; Rocuronium; Pharmacodynamics; TARGET-CONTROLLED INFUSION; NEUROMUSCULAR BLOCKADE; BROMIDE ORG-9426; TIME-COURSE; BOLUS; ANESTHESIA; HALOTHANE;
D O I
10.1007/s00540-018-2543-3
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Purpose Equilibration rate constant is necessary to calculate effect-site concentration, which is useful to control drug effect. We developed pharmacodynamic models for published five compartmental pharmacokinetic models published by Wierda, Szenohradszky, Cooper, Alvarez-Gomez, and McCoy. Methods We used 3848 train-of-four ratios from 15 male and nine female patients (21-76 years; 44-93 kg body weight; 148-181 cm height; and 17.3-29.8 kg/m(2) body mass index) as pharmacodynamic measures, which were collected at the start of 0.6 mg/kg rocuronium administration until the end of the surgery. Effect compartment was assumed to be connected to central compartment of the pharmacokinetic model with equilibration rate constant (k(e0)). Sigmoid E-max model was fitted to describe the relationship between train-of-four ratio and effect-site concentration. Age, sex, and body mass index were assessed as possible covariates of the following model parameters: k(e0), effect-site concentration for half of maximum effect, and the steepness of the effect-site concentration versus effect relationship. Results The duration of neuromuscular monitoring was 69 (37-129) [median (range)] min. All pharmacodynamic models included age and three included sex as significant covariates. K-e0 values ranged between 0.0820 and 0.247 depending on the pharmacokinetic model. The time-courses of the effect-site concentration were similar among the pharmacodynamic models for Wierda, Cooper, and Alvarez-Gomez pharmacokinetic models, which were lower than that for the Szenohradszky pharmacokinetic model. Conclusion Each pharmacodynamic model with the corresponding pharmacokinetic model can be described the time course of rocuronium effect appropriately. The required effect-site concentration of rocuronium for a pharmacodynamic effect was depending on the applied models.
引用
下载
收藏
页码:709 / 716
页数:8
相关论文
共 50 条
  • [1] Rocuronium pharmacodynamic models for published five pharmacokinetic models: age and sex are covariates in pharmacodynamic models
    Kenichi Masui
    Sayaka Ishigaki
    Atsuko Tomita
    Hiroshi Otake
    Journal of Anesthesia, 2018, 32 : 709 - 716
  • [2] PHARMACOKINETIC AND PHARMACODYNAMIC MODELS
    TUCKER, GT
    ADVANCES IN PAIN RESEARCH AND THERAPY, 1990, 14 : 181 - 201
  • [3] Neuromuscular end-point predictive capability of published rocuronium pharmacokinetic/pharmacodynamic models: An observational trial
    Carvalho, Hugo
    Verdonck, Michael
    Eleveld, Douglas J.
    Ramirez, David
    D'Haese, Jan
    Flamee, Panagiotis
    Geerts, Lieselot
    Wylleman, Jasper
    Cools, Wilfried
    Barbe, Kurt
    Struys, Michel M. R. F.
    Poelaert, Jan
    JOURNAL OF CLINICAL ANESTHESIA, 2023, 90
  • [4] Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis
    Wählby, U
    Thomson, AH
    Milligan, PA
    Karlsson, MO
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (04) : 367 - 377
  • [5] Clinical application of pharmacokinetic and pharmacodynamic models
    Billard, V
    ADVANCES IN MODELLING AND CLINICAL APPLICATION OF INTRAVENOUS ANAESTHESIA, 2003, 523 : 57 - 70
  • [6] Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
    Zhang, Longfei
    Xie, Hongbing
    Wang, Yongqiang
    Wang, Hongjuan
    Hu, Jianhe
    Zhang, Gaiping
    FRONTIERS IN VETERINARY SCIENCE, 2022, 9
  • [7] Deterministic identifiability of population pharmacokinetic and pharmacokinetic–pharmacodynamic models
    Vijay K. Siripuram
    Daniel F. B. Wright
    Murray L. Barclay
    Stephen B. Duffull
    Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44 : 415 - 423
  • [8] Development of translational pharmacokinetic-pharmacodynamic models
    Mager, D. E.
    Jusko, W. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (06) : 909 - 912
  • [9] PHARMACOKINETIC PHARMACODYNAMIC MODELS IN ANALGESIC STUDY DESIGN
    VELAGAPUDI, R
    HARTER, JG
    BRUECKNER, R
    PECK, CC
    ADVANCES IN PAIN RESEARCH AND THERAPY, 1991, 18 : 559 - 562
  • [10] In vitro models of infection: Pharmacokinetic/pharmacodynamic correlates
    MacGowan, AP
    FIRST INTERNATIONAL MOXIFLOXACIN SYMPOSIUM - BERLIN, 1999, 2000, : 104 - 110